Precision Oncology Market Stay Ahead with 2030 Market Insights and Trends
Precision Oncology Market Size Was Valued at USD 68.9 Billion in 2022 and is Projected to Reach USD 166.97 Billion by 2030, Growing at a CAGR of 11.7% From 2023-2030.
Within the realm of cancer care, precision oncology is a quickly developing field that customizes treatment plans based on the distinct genetic and molecular features of each patient's cancer. By identifying certain genetic changes that fuel the proliferation of cancer cells and targeting them with precision medicines, this strategy seeks to maximize therapeutic outcomes.
The market for precision oncology has grown significantly as a result of developments in customized medicine, genomics, and molecular profiling technologies. As our understanding of the genetic causes of cancer has grown, tailored treatments and immunotherapies have been developed, opening up new avenues for therapy that are less harmful and more effective.
Molecular diagnostics, next-generation sequencing (NGS), biomarker analysis, and targeted medicines are all part of the precision oncology business. In order to discover genetic mutations, changes, and other molecular abnormalities in a patient's tumor, molecular diagnostics and NGS are essential. This information is critical for making individualized therapy recommendations.
Precision Oncology Market Top Key Players:
Foundation Medicine (USA), Guardant Health (USA), Illumina, Inc. (USA), Roche Molecular Systems (USA), Tempus Labs (USA), Myriad Genetics (USA), Personal Genome Diagnostics Inc. (USA), Exact Sciences Corporation (USA), Thermo Fisher Scientific Inc. (USA), Qiagen (Netherlands), Agilent Technologies (USA), Natera (USA), Strata Oncology (USA), NeoGenomics (USA), Adaptive Biotechnologies (USA), Caris Life Sciences (USA), F. Hoffmann-La Roche AG (Switzerland), Sysmex Corporation (Japan), Bio-Rad Laboratories, Inc. (USA), Bristol Myers Squibb (USA), and Other Major Players.
Grab Your Sample Report - No Cost!
Introspective Market Research is a reliable partner specializing in comprehensive market research studies. Our commitment lies in providing businesses worldwide with valuable insights and strategic guidance through our comprehensive research.
Our Precision Oncology market report ensures accuracy by conducting a precise examination of the industry. We establish a robust foundation for our findings through extensive utilization of primary and secondary sources. To enhance the depth of our evaluation, we employ industry-standard tools such as Porter's Five Forces Analysis, SWOT Analysis, and Price Trend Analysis.
Discount on the Research Report@
Precision Oncology Market Segment Analysis:
The Precision Oncology Market is Segmented into Product Type, Cancer Type, and End-User.
By Product Type
Diagnostics
Therapeutics
By Cancer Type
Breast
Lung
Colorectal
Skin
Prostrate
Stomach
By End-user
Hospitals
Diagnostic Centers
Explore Customization Choices - We're Listening!
Precision Oncology Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
Because of its sophisticated healthcare system, large R&D expenditures, and strong regulatory environment, North America is expected to establish its leadership in the precision oncology market. An increase in partnerships between pharmaceutical companies, academic institutions, and healthcare providers has strengthened the region's leadership position in precision oncology by promoting innovation and technological improvements.
The demand for customized and targeted therapies is driven by the high incidence of cancer cases and the country's well-established healthcare system, which is a major factor in the market's growth. Furthermore, the dominance of North America is further reinforced by the existence of significant market participants and a favorable reimbursement environment.
By Region
North America (US, Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
South America (Brazil, Argentina, Rest of SA)
??? ???????? ???????? ??? ??????? ?? ??? ????????? ?????????:
What is the's expected growth rate for the forecast period 2023-2030?
What will the size be within the forecasted time frame?
What are the important factors that will determine the fate of the Precision Oncology industry over the next several years?
Who are the leading competitors, and what are their winning methods for gaining important characteristics in the Precision Oncology industry?
What are the major trends that are
Precision Oncology Market Size Was Valued at USD 68.9 Billion in 2022 and is Projected to Reach USD 166.97 Billion by 2030, Growing at a CAGR of 11.7% From 2023-2030.
Within the realm of cancer care, precision oncology is a quickly developing field that customizes treatment plans based on the distinct genetic and molecular features of each patient's cancer. By identifying certain genetic changes that fuel the proliferation of cancer cells and targeting them with precision medicines, this strategy seeks to maximize therapeutic outcomes.
The market for precision oncology has grown significantly as a result of developments in customized medicine, genomics, and molecular profiling technologies. As our understanding of the genetic causes of cancer has grown, tailored treatments and immunotherapies have been developed, opening up new avenues for therapy that are less harmful and more effective.
Molecular diagnostics, next-generation sequencing (NGS), biomarker analysis, and targeted medicines are all part of the precision oncology business. In order to discover genetic mutations, changes, and other molecular abnormalities in a patient's tumor, molecular diagnostics and NGS are essential. This information is critical for making individualized therapy recommendations.
Precision Oncology Market Top Key Players:
Foundation Medicine (USA), Guardant Health (USA), Illumina, Inc. (USA), Roche Molecular Systems (USA), Tempus Labs (USA), Myriad Genetics (USA), Personal Genome Diagnostics Inc. (USA), Exact Sciences Corporation (USA), Thermo Fisher Scientific Inc. (USA), Qiagen (Netherlands), Agilent Technologies (USA), Natera (USA), Strata Oncology (USA), NeoGenomics (USA), Adaptive Biotechnologies (USA), Caris Life Sciences (USA), F. Hoffmann-La Roche AG (Switzerland), Sysmex Corporation (Japan), Bio-Rad Laboratories, Inc. (USA), Bristol Myers Squibb (USA), and Other Major Players.
Grab Your Sample Report - No Cost!
Introspective Market Research is a reliable partner specializing in comprehensive market research studies. Our commitment lies in providing businesses worldwide with valuable insights and strategic guidance through our comprehensive research.
Our Precision Oncology market report ensures accuracy by conducting a precise examination of the industry. We establish a robust foundation for our findings through extensive utilization of primary and secondary sources. To enhance the depth of our evaluation, we employ industry-standard tools such as Porter's Five Forces Analysis, SWOT Analysis, and Price Trend Analysis.
Discount on the Research Report@
Precision Oncology Market Segment Analysis:
The Precision Oncology Market is Segmented into Product Type, Cancer Type, and End-User.
By Product Type
Diagnostics
Therapeutics
By Cancer Type
Breast
Lung
Colorectal
Skin
Prostrate
Stomach
By End-user
Hospitals
Diagnostic Centers
Explore Customization Choices - We're Listening!
Precision Oncology Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
Because of its sophisticated healthcare system, large R&D expenditures, and strong regulatory environment, North America is expected to establish its leadership in the precision oncology market. An increase in partnerships between pharmaceutical companies, academic institutions, and healthcare providers has strengthened the region's leadership position in precision oncology by promoting innovation and technological improvements.
The demand for customized and targeted therapies is driven by the high incidence of cancer cases and the country's well-established healthcare system, which is a major factor in the market's growth. Furthermore, the dominance of North America is further reinforced by the existence of significant market participants and a favorable reimbursement environment.
By Region
North America (US, Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
South America (Brazil, Argentina, Rest of SA)
??? ???????? ???????? ??? ??????? ?? ??? ????????? ?????????:
What is the's expected growth rate for the forecast period 2023-2030?
What will the size be within the forecasted time frame?
What are the important factors that will determine the fate of the Precision Oncology industry over the next several years?
Who are the leading competitors, and what are their winning methods for gaining important characteristics in the Precision Oncology industry?
What are the major trends that are
9 months ago
